Articles published by Can-Fite BioPharma Ltd.
![](https://mms.businesswire.com/media/20221125005018/en/1567498/4/logo_-_sq_400x400_300dpi_%28002%29.jpg.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20221102005565/en/1567498/4/logo_-_sq_400x400_300dpi_%28002%29.jpg.jpg)
![](https://mms.businesswire.com/media/20221025005244/en/1612213/4/logo_-_sq_400x400_300dpi.jpg)
![](https://mms.businesswire.com/media/20221013005106/en/1567498/4/logo_-_sq_400x400_300dpi_%28002%29.jpg.jpg)
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
October 13, 2022
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220912005019/en/1567563/4/logo_-_sq_400x400_300dpi_%28002%29.jpg.jpg)
![](https://mms.businesswire.com/media/20220825005061/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220823005373/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220817005358/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220822005193/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220711005256/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220629005222/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220624005117/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220609005293/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220526005065/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220516005099/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220502005267/en/1439189/5/May_2_2022_press_release_image.jpg)
![](https://mms.businesswire.com/media/20220405005268/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220328005011/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220324005121/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220314005244/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220131005278/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
January 31, 2022
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220113005463/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20220110005567/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20220105005462/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20211229005181/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20211220005270/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20211207005199/en/779612/5/Can-Fite_logo_no_shadow.jpg)
![](https://mms.businesswire.com/media/20211124005464/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20211123005715/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
November 23, 2021
Via Business Wire
Tickers
CANF
![](https://mms.businesswire.com/media/20211112005231/en/779612/5/Can-Fite_logo_no_shadow.jpg)
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
November 12, 2021
Via Business Wire
Tickers
CANF
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.